BioCentury | Nov 14, 2020
Politics, Policy & Law

U.K.’s opportunity as changes come to MHRA, NICE

On the cusp of a new era outside of Europe, the U.K. has an opportunity to create an innovative and interconnected regulatory and reimbursement system that can attract biopharma by accelerating patient...
BioCentury | Aug 11, 2020
Finance

AI play Atomwise to build internal pipeline with $123M series B

...investor Sanabil Investments led the series B (see “Atomwise’s Series B Investors”).TargetsPIM3 -- Pim-3PIM1 -- Pim-1 Virginia...
BioCentury | May 4, 2020
Deals

Stemline takeout gives Menarini U.S. oncology beachhead

...reach the U.S. market in the coming years. MEN1703, its dual inhibitor of FLT3 and PIM1...
...HER2 (EGFR2;ErbB2; neu) - Epidermal growth factor receptor 2 PI3K - Phosphoinositide 3-kinase PIM1 - Pim-1...
BioCentury | Jan 28, 2020
Company News

Jan. 27 Company Quick Takes: Enhertu meets in pivotal gastric cancer study; plus Biocon-Mylan, CMS, Lilly-Boehringer, Ningbo-Genentech

...linagliptin (BI 1356) AstraZeneca plc Daiichi Pharmaceutical Co. Ltd. Biocon Ltd. Mylan N.V. Boehringer Ingelheim GmbH Eli Lilly and Co. Genentech Inc. Pim-1 (PIM1) Epidermal...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

X-37 raised a $14.5 million series A to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio led Thursday’s round, with participation from Alpha Intelligence...
BioCentury | Oct 17, 2019
Financial News

Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

Ascentage sets Hong Kong IPO terms Ascentage Pharma Group International would raise HK$404.4 million ($51.6 million) and be valued at HK$6.9 billion ($876.4 million) if it prices its Hong Kong IPO at the mid-point of...
BioCentury | Jul 19, 2019
Company News

July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more

Mallinckrodt licenses RNAi candidate from Silence Mallinckrodt plc (NYSE:MNK) obtained an exclusive, worldwide license to C3-targeted RNAi therapy SLN500 from Silence Therapeutics plc (LSE:SLN), plus options to license up to two additional complement-targeted preclinical candidates....
BioCentury | May 15, 2019
Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

DISEASE CATEGORY: Cancer INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In CML patients, levels of PIM2 mRNA...
BioCentury | Nov 9, 2018
Clinical News

Mallinckrodt Niemann-Pick disease therapy fails pivotal trial

Mallinckrodt plc (NYSE:MNK) said VTS-270 showed no significant separation from placebo in a Phase IIb/III trial to treat Niemann-Pick disease type C1 (NPC1). Mallinckrodt CSO and EVP Steven Romano disclosed the result on a conference...
BioCentury | Nov 6, 2018
Clinical News

Mallinckrodt Niemann-Pick disease therapy fails pivotal trial

Mallinckrodt plc (NYSE:MNK) said VTS-270 showed no significant separation from placebo in a Phase IIb/III trial to treat Niemann-Pick disease type C1 (NPC1). Mallinckrodt CSO and EVP Steven Romano disclosed the result on a conference...
Items per page:
1 - 10 of 91